Email this article Treatment of patients with arterial hypertension and other stroke risk factors in clinical practice. The PROGNOS program
- Authors: Bubnova M.G.1, Oganov R.G.1, Bubnova MG1, Oganov RG1
-
Affiliations:
- ФГУ Государственный научно-исследовательский Центр профилактической медицины Росмедтехнологий
- Issue: Vol 81, No 9 (2009)
- Pages: 19-23
- Section: Editorial
- URL: https://journal-vniispk.ru/0040-3660/article/view/30481
- ID: 30481
Cite item
Full Text
Abstract
Aim. To analyse recent data on the treatment of arterial hypertension (AH) with other risk factors (RF) of cerebral stroke in the Russian Federation, assessment of effects of antihypertensive treatment with a combined drug Hyzaar on the risk of cardiovascular complications (including cerebral stroke), on affection of target organs and metabolic factors of atherosclerosis.
Material and methods. A total of 500 outpatients with primary AH and risk factors including the risk of stroke received Hyzaar (losartan 50/100 mg and hydrochlorthiaside 12.5/25 mg) for one year.
Results. More frequent RF in hypertensive patients are the following: high blood cholesterol (86.7%), left ventricular hypertrophy (53.2%), familial history of AH (74.2%). A combination of three and two RF occurs in 49.1 and 37% hypertensive patients, respectively. A 6-month treatment with Hyzaar lowered systolic blood pressure by 28.4 mm Hg and diastolic one by 15.4 mm Hg. The target blood pressure was achieved in 83.5%. Real clinical practice showed that administration of a target Hyzaar dose for 6 months leads to a 6.5% regress of left ventricular hypertrophy, an 11% decrease of total cholesterol, a 4% decrease of glucose and a 8.9% decrease of uric acid.
Conclusion. A control of AH and correction of RF in hypertensive patients with a high RF of stroke and other cardiovascular complications is real in use of adequate antihypertensive therapy.
Material and methods. A total of 500 outpatients with primary AH and risk factors including the risk of stroke received Hyzaar (losartan 50/100 mg and hydrochlorthiaside 12.5/25 mg) for one year.
Results. More frequent RF in hypertensive patients are the following: high blood cholesterol (86.7%), left ventricular hypertrophy (53.2%), familial history of AH (74.2%). A combination of three and two RF occurs in 49.1 and 37% hypertensive patients, respectively. A 6-month treatment with Hyzaar lowered systolic blood pressure by 28.4 mm Hg and diastolic one by 15.4 mm Hg. The target blood pressure was achieved in 83.5%. Real clinical practice showed that administration of a target Hyzaar dose for 6 months leads to a 6.5% regress of left ventricular hypertrophy, an 11% decrease of total cholesterol, a 4% decrease of glucose and a 8.9% decrease of uric acid.
Conclusion. A control of AH and correction of RF in hypertensive patients with a high RF of stroke and other cardiovascular complications is real in use of adequate antihypertensive therapy.
About the authors
Marina Gennad'evna Bubnova
ФГУ Государственный научно-исследовательский Центр профилактической медицины Росмедтехнологий
Email: mbubnova@gnicpm.ru
д.м.н., проф., вед. н.с., лаборатория сочетанной патологии, НИЦ профилактической медицины; ФГУ Государственный научно-исследовательский Центр профилактической медицины Росмедтехнологий
Rafael' Gegamovich Oganov
ФГУ Государственный научно-исследовательский Центр профилактической медицины Росмедтехнологийакад. РАМН, проф., директор НИЦ профилактической медицины; ФГУ Государственный научно-исследовательский Центр профилактической медицины Росмедтехнологий
M G Bubnova
R G Oganov
References
- Шальнова С. А., Деев А. Д., Оганов Р. Г. и др. Распространенность артериальной гипертонии среди населения России. Укреп. здоровья и проф. забол. 2001; 2: 3-7.
- Collins R., Mc Mahon S. Blood pressure, antihypertensive drug treatment and risks of stroke and of coronary heart disease. Br. Med. Bull. 1994; 50: 272-298.
- Keli S., Bloemberg B., Kromhout D. Predictive value of repeated systolic blood pressure measurements for stroke risk: The Zutphen Study. Stroke 1992; 23: 347-351.
- Sacco R. L., Benjamin H. L., Broderick I. P. et al. American Heart Association prevention conference. IV. Prevention and rehabilitation of stroke. Risk factors. Stroke 1997; 28: 1507- 1517.
- Mohr J. P., Albers G. W., Amarenco P. et al. American Heart Association prevention conference. IV. Prevention and rehabilitation of stroke. Etiology of Stroke. Stroke 1997;28: 1501- 1506.
- Brown R. D., Whisnant J. P., Sicks R. D. et al. Stroke incidence, prevalence, and survival: Secular trends in Rochester, Minnesota, through 1989. Stroke 1996; 27: 373-380.
- McMahon S., Rodgers A. The epidemiologic association between blood pressure and stroke: Implication for primary and secondary prevention. Hypertens. Res. 1994; 17 (suppl. 1): S23-S32.
- Materson B. L., Reda D. L., Cushman W. C. et al. Single-drug therapy for hypertension in men. A comparison of six antihypertension agents with placebo. N. Engl. J. Med. 1993; 328: 914-921.
- Dahlof B., Devereux R. B., Kjeldsen S. E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
- Шевченко О. П., Праскурничий Е. А., Яхно Н. Н., Парфенов В. А. Артериальная гипертония и церебральный инсульт. М.; 2001. 192.
- Devgun M., Dhillon H. Importance of diural variations on clinical value and interpretation of serum urate measurements. J. Clin. Pathol. 1992; 45: 110-113.
- Soffer B., Wright J. et al. Effect of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112-117.
Supplementary files
